American Association for Cancer Research
Browse
00085472can162400-sup-171199_2_supp_3765012_ghhgy9_eps_zip.zip (15.09 MB)

Supplementary figure 2 from Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling

Download (15.09 MB)
software
posted on 2023-03-31, 01:05 authored by Whitney S. Henry, Tyler Laszewski, Tiffany Tsang, Francisco Beca, Andrew H. Beck, Sandra S. McAllister, Alex Toker

Supplementary figure 2. Aspirin treatment results in activation of AMPK and decrease in mTORC1 signaling.

Funding

NIH

DOD

CDMRP

Howard Hughes Medical Institute

History

ARTICLE ABSTRACT

Despite the high incidence of oncogenic mutations in PIK3CA, the gene encoding the catalytic subunit of PI3K, PI3K inhibitors have yielded little clinical benefit for breast cancer patients. Recent epidemiologic studies have suggested a therapeutic benefit from aspirin intake in cancers harboring oncogenic PIK3CA. Here, we show that mutant PIK3CA-expressing breast cancer cells have greater sensitivity to aspirin-mediated growth suppression than their wild-type counterparts. Aspirin decreased viability and anchorage-independent growth of mutant PIK3CA breast cancer cells independently of its effects on COX-2 and NF-κB. We ascribed the effects of aspirin to AMP-activated protein kinase (AMPK) activation, mTORC1 inhibition, and autophagy induction. In vivo, oncogenic PIK3CA-driven mouse mammary tumors treated daily with aspirin resulted in decreased tumor growth kinetics, whereas combination therapy of aspirin and a PI3K inhibitor further attenuated tumor growth. Our study supports the evaluation of aspirin and PI3K pathway inhibitors as a combination therapy for targeting breast cancer. Cancer Res; 77(3); 790–801. ©2016 AACR.